Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo-controlled D-CARE study
12 března, 2021 6:13 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 501 Authors: Robert E. Coleman, Dianne Finkelstein,...
De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study
12 března, 2021 6:11 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 507 Authors: Valentina Guarneri, Maria Vittoria Dieci,...
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease- -free survival (DFS) results
12 března, 2021 6:08 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: 506 Authors: Helena Margaret Earl, Louise Hiller,...
Persephone Demonstrates Noninferiority of Shorter Duration Adjuvant Trastuzumab in HER2-Positive Breast Cancer
12 března, 2021 6:06 pmA 6-month duration of adjuvant trastuzumab with chemotherapy was found to be noninferior to 12 months with chemotherapy, which is currently...
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score
12 března, 2021 6:03 pmMeeting: 2018 ASCO Annual Meeting Track: Breast Cancer—Local/Regional/Adjuvant Abstract number: LBA1 Authors: Joseph A. Sparano, Robert James...
TAILORx: Many Women With Early Breast Cancer Can Avoid Chemotherapy
12 března, 2021 6:01 pmJune 4, 2018 Endocrine therapy (ET) alone was noninferior to ET plus chemotherapy for women with estrogen receptor (ER)−positive,...
KARCINOM PRSU NA ASCO 2018
12 března, 2021 5:40 pmNejvětší novinky prezentované na posledních konferencích ASCO se zpravidla netýkaly karcinomu prsu, ale jiných solidních nádorů, jako je maligní melanom, karcinom...
VAKCÍNA NA BÁZI DENDRITICKÝCH BUNĚK (DENDRITIC CELL VACCINE, DCVAC) PODÁVANÁ S CHEMOTERAPIÍ PACIENTKÁM S EPITELIÁLNÍM OVARIÁLNÍM KARCINOMEM (EPITHELIAL OVARIAN CARCINOMA, EOC) PO PRIMÁRNÍ CHIRURGICKÉ LÉČBĚ (PRIMARY DEBULKING SURGERY, PDS): PRŮBĚŽNÁ ANALÝZA OTEVŘENÉHO RANDOMIZOVANÉHO MULTI-CENTRICKÉHO KLINICKÉHO HODNOCENÍ FÁZE 2
12 března, 2021 4:52 pmKongres: 2018 ASCO Annual Meeting Sekce: Genitourinární Autoři: Lukáš Rob, Peter Mallmann, Pawel Knapp, Bohuslav Melichar, Jaroslav Klát,...
OLAPARIB COMBINED WITH ABIRATERONE IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): A RANDOMIZED PHASE II TRIAL
12 března, 2021 4:45 pmMeeting: 2018 ASCO Annual Meeting Track: Genitourinary (Prostate) Cancer Abstract number: 5003 Citation: J Clin Oncol 36,...
ADDING OLAPARIB TO ABIRATERONE PROLONGS RPFS IN MCRPC
12 března, 2021 4:43 pmJune 4, 2018 PARP inhibition with olaparib plus antihormonal therapy with abiraterone resulted in significantly prolonged radiologic progression-free survival...